SILO PHARMA, INC. Preferred Stock Dividends, Income Statement Impact
SILO PHARMA, INC. (SILO) reported Preferred Stock Dividends, Income Statement Impact of $1.40 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2023-03-24
- SILO PHARMA, INC. preferred stock dividends, income statement impact for the quarter ending 2021-12-31 was $0.00.
- SILO PHARMA, INC. preferred stock dividends, income statement impact for the quarter ending 2021-09-30 was $0.00.
- SILO PHARMA, INC. preferred stock dividends, income statement impact for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- SILO PHARMA, INC. preferred stock dividends, income statement impact for the quarter ending 2021-03-31 was $1.40M.
- SILO PHARMA, INC. preferred stock dividends, income statement impact for fiscal 2021 was $1.40M, a 1934.78% increase from fiscal 2020.
- SILO PHARMA, INC. preferred stock dividends, income statement impact for fiscal 2020 was $69.00K.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $0.00 derived: sum of 2 quarters · filed 2023-03-24 | $0.00 derived: sum of 3 quarters · filed 2023-03-24 | $1.40M 10-K · filed 2023-03-24 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $1.40M 10-Q · filed 2022-11-10 | $1.40M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | $1.40M 10-Q · filed 2022-08-01 | $1.40M derived: sum of 3 quarters · filed 2022-08-01 | $1.40M derived: sum of 4 quarters · filed 2022-08-01 |
| 2021-03-31 | $1.40M 10-Q · filed 2022-05-13 | $1.40M derived: sum of 2 quarters · filed 2022-05-13 | $1.40M derived: sum of 3 quarters · filed 2022-05-13 | $1.47M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $0.00 derived: sum of 2 quarters · filed 2022-03-28 | $69.00K derived: sum of 3 quarters · filed 2022-03-28 | $69.00K 10-K · filed 2022-03-28 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $69.00K derived: sum of 2 quarters · filed 2021-11-10 | $69.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $69.00K 10-Q · filed 2021-08-13 | $69.00K 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |